DIABETES THERAPY TO IMPROVE MUSCLE MASS IN CF

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。由于胰岛素分泌缺陷导致糖耐量受损的CF患者不常规地用外源性胰岛素治疗，因为空腹血糖和血红蛋白Alc水平正常。这种做法忽略了胰岛素缺乏对蛋白质代谢的潜在有害影响。我们假设，长期使用胰岛素或口服降糖药治疗，将导致胰岛素缺乏的非糖尿病CF成人的蛋白质血管紧张素转换酶的改善。将进行一项多中心、前瞻性、安慰剂对照、双盲干预试验，用三种药物之一治疗葡萄糖不耐受的成人CF患者6个月：胰岛素、格列吡嗪、曲格列酮或安慰剂。我们将评估这些药物对蛋白质合成和分解、肺功能和身体组成的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. CF patients with impaired glucose tolerance due to defective insulin secretion are not routinely treated with exogenous insulin since fasting glucose and hemoglobin Alc levels are normal. This practice ignores the potentially detrimental effects of insulin deficiency on protein metabolism. We hypothesize that chronic treatment with either insulin or an oral hypoglycemic agent will lead to improved protein anabolism in insulin-deficient, non-diabetic CF adults. A multicenter, prospective, placebo-controlled, double-blinded intervention trail will be undertaken to treat glucose intolerant adult CF patients for six months with one of three agents: insulin, glipizide, troglitazone or placebo. We will evaluate the effects of these agents on protein synthesis and breakdown, pulmonary function, and body composition.